S. X. Zhang
YOU?
Author Swipe
View article: Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC
Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC Open
Background PD-1 inhibitors exhibit efficacy in managing unresectable/metastatic driver gene-negative NSCLC, albeit with potential immune-related adverse events (irAEs). Among these, immune checkpoint inhibitor-associated myocarditis (ICI-M…
View article: POS1423 ASSESSING THE EFFECT OF ANTIHYPERTENSIVE DRUGS ON SYSTEMIC LUPUS ERYTHEMATOSUS： A MENDELIAN RANDOMIZATION STUDY
POS1423 ASSESSING THE EFFECT OF ANTIHYPERTENSIVE DRUGS ON SYSTEMIC LUPUS ERYTHEMATOSUS： A MENDELIAN RANDOMIZATION STUDY Open
View article: AB0257 GENETIC EVIDENCE REVEALS A CAUSAL ROLE BETWEEN LEUKOCYTE COUNTS AND THE RISK OF RHEUMATOID ARTHRITIS
AB0257 GENETIC EVIDENCE REVEALS A CAUSAL ROLE BETWEEN LEUKOCYTE COUNTS AND THE RISK OF RHEUMATOID ARTHRITIS Open
View article: AB1049 THE STATUS OF BREG CELLS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
AB1049 THE STATUS OF BREG CELLS IN PATIENTS WITH ANKYLOSING SPONDYLITIS Open
View article: AB0195 GENETIC ASSOCIATION BETWEEN INTERLEUKIN-17 AND SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS
AB0195 GENETIC ASSOCIATION BETWEEN INTERLEUKIN-17 AND SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS Open
Background The pathogenesis of rheumatoid arthritis (RA) is immune imbalance, in which various inflammatory immune cells and pro-inflammatory factors are involved[1]. In particular, interleukin-17 (IL-17) is a potent pro-inflamm…
View article: AB0145 GENETIC EVIDENCE REVEALS A CAUSAL ROLE OF BLOOD LEUKOCYTE COUNTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
AB0145 GENETIC EVIDENCE REVEALS A CAUSAL ROLE OF BLOOD LEUKOCYTE COUNTS IN SYSTEMIC LUPUS ERYTHEMATOSUS Open
Background Blood leukocyte counts are important biomarkers for the onset of systemic lupus erythematosus (SLE)[1-3]. However, the causal relationship is unclear. Objectives We implement a two-sample Mendelian Randomization (MR) analysis to…
View article: AB1317 EFFICACY AND SAFETY OF COVID-19 VACCINES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH DIFFERENT ANTI-RHEUMATIC THERAPIES
AB1317 EFFICACY AND SAFETY OF COVID-19 VACCINES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH DIFFERENT ANTI-RHEUMATIC THERAPIES Open
Background The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has led to rapid progress in vaccine development to prevent the spread of the disease. Rheumatoid arthritis (RA) is a common s…
View article: AB0001 GUT MICROBIOTA IMBALANCE IN INFLAMMATORY ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
AB0001 GUT MICROBIOTA IMBALANCE IN INFLAMMATORY ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Open
Background Inflammatory arthritis (IA) is a group of autoimmune arthritis characterized by a pro-inflammatory/anti-inflammatory disbalance of local mediators[1][2]. Research on the influence of gut microbiota(GM) on systemic IA has explode…
View article: POS0437 GENETICALLY DETERMINED TELOMERE LENGTH AND THE RISK OF ANKYLOSING SPONDYLITIS
POS0437 GENETICALLY DETERMINED TELOMERE LENGTH AND THE RISK OF ANKYLOSING SPONDYLITIS Open
Background Telomeres are unique chromatin structures at the ends of eukaryotic chromosomes and play a crucial role in maintaining genomic stability. Ankylosing spondylitis(AS) is a chronic degenerative inflammatory disease that occurs prim…
View article: POS0750 THE STATUS OF BREGS AND BREG-RELATED CYTOKINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
POS0750 THE STATUS OF BREGS AND BREG-RELATED CYTOKINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Open